{
    "clinical_study": {
        "@rank": "72079", 
        "acronym": "EMAN-Anaemia", 
        "arm_group": [
            {
                "arm_group_label": "EMAN", 
                "arm_group_type": "Active Comparator", 
                "description": "Electronic auditing via synchronised blood tests and monthly dosing ESA and Home delivery of ESA from Pharmacy if required"
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "No Intervention", 
                "description": "Standard Outpatient Care with usual blood tests and follow up, and varied ESA dosing and frequency times. Patients are responsible for collecting their own ESA from Pharmacy"
            }
        ], 
        "brief_summary": {
            "textblock": "Aims:\n\n        1. To establish an electronic process for CKD anaemia management using monthly\n           synchronized dosing of erythrocyte stimulating agents (ESA).\n\n        2. To compare this electronic process with \"present anaemia management\" in the traditional\n           outpatient setting.\n\n        3. To monitor Hb targets and clinical endpoints of study groups to model a larger\n           multicentre study focusing on these endpoints."
        }, 
        "brief_title": "Study of the Effect of Synchronised Anaemia Management in Chronic Kidney Disease", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Kidney Failure, Chronic", 
            "Anemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Kidney Diseases", 
                "Kidney Failure, Chronic", 
                "Renal Insufficiency", 
                "Renal Insufficiency, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "CKD Stages 3 to 5 Subjects will be randomised and stratified according to Age, Gender, CKD\n      Stage, Known Cardiovascular Disease, Diabetes and ESA Type into EMAN vs. Control\n\n      Details of EMAN synchronization and Dosing:\n\n      Monthly dose of ESA is calculated by:\n\n      Monthly dose = present dose x (28/present frequency (days))\n\n      Synchronization will be achieved by using the formula: \"Synchronization dose of ESA =\n      (28-Days until next injection is due)/28 x monthly dose of ESA\n\n      The dose of ESA/C.E.R.A. should be adjusted to maintain the individual patient's haemoglobin\n      within a range of 11\u00b1 1.0 g/dL of the reference haemoglobin concentration ie. between 10.0\n      and 12.0 g/dL\n\n      Haemoglobin Value Corrective Adjustment\n\n        -  A single value >13 g/dL Interrupt treatment until Hb falls below 12 g/dL then re-start\n           treatment at 50% of previous dose\n\n        -  A single value <9 g/dL Increase dose by 50%\n\n        -  Difference between two consecutive Hb values indicates \u22652 g/dL increase Reduce dose by\n           50%\n\n        -  Difference between two consecutive Hb values indicates \u22652 g/dL decrease Increase dose\n           by 50%\n\n        -  >11.5 g/dL and <13 g/dL AND deviation from reference value is >1g/dL. Reduce dose by\n           25%\n\n        -  <10.5 g/dL and >9 g/dL AND deviation from reference value is >1g/dL. Increase dose by\n           25%\n\n        -  >12 g/dL Reduce dose by 25%\n\n        -  <10 g/dL Increase dose by 25%\n\n      Statistics:\n\n      Audit of present practice suggests CKD patients achieve only 30% on target (Hb 10-12g/dL)\n      while well audited dialysis units in our service can achieve 60% at target.\n\n      If an improvement from 30% to 60% is expected in the EMAN verses Control arm then 100\n      patients (50 in each group) would be required to show a significant difference p<0.05 with\n      85% power.\n\n      Patients will be analysed on an intention to treat basis Primary and Secondary Endpoint data\n      will be compared between study and control groups using unpaired student t-tests after\n      normalisation of data as required and/or chi squared analysis.\n\n      Statistical significance will be taken at p<0.05."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent\n\n          -  Age > 18 years\n\n          -  Chronic renal anaemia already on ESA therapy as defined by Pharmaceutical Benefits\n             Scheme Criteria\n\n        Exclusion Criteria:\n\n          -  Pregnancy\n\n          -  Significant acute bleeding such as overt gastrointestinal bleeding\n\n          -  A known haematological cause for anaemia\n\n          -  Known metastatic malignancy\n\n          -  Present participation in another interventional clinical trial \u2022 Known\n             hypersensitivity to recombinant human erythropoietin, polyethylene glycol or to any\n             constituent of the study medication"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "102", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01763242", 
            "org_study_id": "HREC: 2010.267"
        }, 
        "intervention": {
            "arm_group_label": "EMAN", 
            "description": "See details on ESA Synchronization and Dosing in Detailed Description Above", 
            "intervention_name": "EMAN", 
            "intervention_type": "Other", 
            "other_name": [
                "Synchronised Blood Testing", 
                "Electronic upload of Blood Results", 
                "Synchronised ESA dosing monthly", 
                "Home delivery of ESA"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "CKD, Anaemia, Synchronization, Monthly dosing, Home Delivery", 
        "lastchanged_date": "January 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Footscray", 
                    "country": "Australia", 
                    "state": "Victoria", 
                    "zip": "3011"
                }, 
                "name": "Western Health"
            }
        }, 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "2", 
        "official_title": "EMAN-Anaemia: An Open Labelled Randomised Control Trial of the Synchronized Electronic MANagement of Anaemia in Chronic Kidney Disease (CKD) Compared to Usual Care Anaemia Management", 
        "other_outcome": {
            "measure": "Sub-Analysis of Outcomes by ESA Type", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "overall_official": {
            "affiliation": "Western Health, Australia", 
            "last_name": "Craig L Nelson, MBBSFRACPPhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Australia: Human Research Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Haemoglobin (Hb) Targets: % above/within/below target ; % Time Hb above/within/below Target ie. Hb 10 to 12g/dL.", 
            "measure": "Haemoglobin", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01763242"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Western Health, Australia", 
            "investigator_full_name": "Dr Craig Nelson", 
            "investigator_title": "Head of Unit - Nephrology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Same day and Non Same Day Hospitalisation analysis, Total Hospitalisations", 
                "measure": "All Cause Hospitalisation", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Outpatient Review Numbers", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Primary Care review Numbers", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Cardiovascular Hospitalisation", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Cerebrovascular Hospitalisation", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Peripheral Vascular Hospitalisation", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Venous and Arterial", 
                "measure": "Thrombosis Events", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Dialysis and Renal transplantation", 
                "measure": "Renal Replacement Therapy Commencement", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Deaths", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Quality of Life", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Missed Doses of ESA", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Fe Targets", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Blood Transfusion Numbers", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Fe Transfusion Numbers", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Total Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Anaemia Co-Ordinator Time", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Pharmacy Time", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Courier Costs", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Ambulance Transfer Numbers", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "N Terminal Pro-Brain Natruretic Peptide, Interleukin-6, Tumour Necrosis Factor alpha, High Sensitivity C Reactive Protein", 
                "measure": "Cardiac and Vascular Biomarker Analysis", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Western Health, Australia", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Western Health, Australia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}